Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of propranolol loaded SLN for transdermal delivery: characterization and skin deposition studies.
Ther Deliv
January 2025
Medical Biomaterials Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran.
Aim: The study aimed to formulate solid lipid nanoparticles (SLNs) for the transdermal delivery of PPL to improve skin retention and efficacy.
Materials And Method: The particle size distribution of SLNs was determined and the morphology of SLNs was also analyzed by SEM. , and evaluations were done for PPL loaded SLN.
Beta-adrenergic receptor antagonist propranolol prevents bisphosphonate-related osteonecrosis of the jaw by promoting osteogenesis.
J Dent Sci
January 2025
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Background/purpose: Bisphosphonate-related osteonecrosis of the jaw (BRONJ), a complication arising from the use of bisphosphonates (BPs), inflicts long-term suffering on patients. Currently, there is still a lack of effective treatments. This study aimed to explore the preventive effects of propranolol (PRO) on BRONJ in vitro and in vivo, given PRO's potential in bone health enhancement.
View Article and Find Full Text PDFPropranolol as a Novel Therapeutic Approach for Post-Stroke Anxiety: A Clinical Review and Future Directions.
Cureus
December 2024
Neuroscience, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR.
Stroke remains a leading cause of death globally, with survivors facing both physical and psychological challenges. While acute stroke treatment has improved, many patients develop post-stroke anxiety (PSA), particularly generalized anxiety disorder. PSA represents a significant clinical challenge as most stroke survivors suffer from it.
View Article and Find Full Text PDFOnce a day administration of R(+) propranolol is sufficient to block vasculogenesis in a xenograft model of infantile hemangioma.
J Vasc Anom (Phila)
September 2024
Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
Objectives: Infantile hemangioma (IH) is a benign vascular tumor that occurs in 5% of infants, predominantly in female and preterm neonates. Propranolol is the mainstay of treatment for IH. Given the short half-life of propranolol regarding β-adrenergic receptor inhibition as well as its side effects, propranolol is administered to infants 2-3 times daily with 1 mg/kg/dose.
View Article and Find Full Text PDFEvaluation of Five Ready-to-Use Bases for the Topical Administration of Propranolol Hydrochloride to Treat Infantile Hemangioma.
Pharmaceutics
January 2025
Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70125 Bari, Italy.
: Since 2008, following clinical studies conducted on children that revealed the ability of the β-adrenergic antagonist propranolol to inhibit capillary growth in infantile hemangiomas (IHs), its oral administration has become the first-line treatment for IHs. Although oral propranolol therapy at a dosage of 3 mg/kg/die is effective, it can cause systemic adverse reactions. This therapy is not necessarily applicable to all patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!